Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The aim of the study was to assess risedronate's effect on bone mineral density in postmenopausal women with rheumatoid arthritis receiving glucocorticoids. We carried out a two center, 2 year, double-masked, placebo-controlled trial with a third year of nontreatment follow-up. We studied 120 women requiring long-term glucocorticoid therapy at > 2.5 mg/day prednisolone randomized to treatment with daily placebo; daily 2.5 mg risedronate; or cyclical 15 mg risedronate (2 out of 12 weeks). At 97 weeks, bone mineral density was maintained at the lumbar spine (+1.4%) and trochanter (+0.4%) in the daily 2.5 mg risedronate group, while significant bone loss occurred in the placebo group (-1.6%, p = 0.03; and 4.0%, p < 0.005, respectively). At the femoral neck, there was a nonsignificant bone loss in the daily 2.5 mg risedronate group (-1.0%) while in the placebo group bone mass decreased significantly (-3.6%, p < 0.001). The difference between placebo and daily 2.5 mg risedronate groups was significant at the lumbar spine (p = 0.009) and trochanter (p = 0.02) but did not reach statistical significance at the femoral neck. Although not significantly different from placebo at the lumbar spine, the overall effect of the cyclical regimen was similar to that of the daily 2.5 mg risedronate regimen. Treatment withdrawal led to bone loss in the risedronate groups that was significant at the lumbar spine. A similar number of patients experienced adverse events (including upper gastrointestinal events) across treatment groups and risedronate was generally well tolerated. Thus risedronate preserves bone mass in postmenopausal women with rheumatoid arthritis receiving glucocorticoids while patients receiving a placebo have significant bone loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Risedronate is also approved for treatment to increase bone mass in men with osteoporosis and for the prevention and treatment of osteoporosis in men and women who are either initiating or taking glucocorticoids [75].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [75]
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615 · cited 1×
“As inhibitors of bone resorption, bisphosphonates are becoming widely used in the management of postmenopausal osteoporosis [ 10 ].”
BackgroundSelf-citationPrevalence and incidence of vertebral deformities
Melton, L. J., Lane, A. W., Cooper, C., Eastell, R., O'Fallon, W. M., & Riggs, B. L. (1993) · Osteoporosis International · doi:10.1007/bf01623271 · Cited by 517
Self-citationPeel, N. F., Moore, D. J., Barrington, N. A., Bax, D. E., & Eastell, R. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.10.801 · Cited by 379
Self-citationA UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update
Eastell, R., Reid, D. M., Compston, J., Cooper, C., Fogelman, I., Francis, R. M., Hosking, D. J., Purdie, D. W., Ralston, S. H., Reeve, J., et al. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00408.x · Cited by 315 · cited 2×
“After low bone mass has developed, the use of other agents such as bisphosphonates has been recommended [ 4 ].”
BackgroundSelf-citationHAHN, T. J., HALSTEAD, L. R., & BARAN, D. T. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-1-111 · Cited by 308
Dykman, T. R., Gluck, O. S., Murphy, W. A., Hahn, T. J., & Hahn, B. H. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280402 · Cited by 281
Glucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Risk of vertebral fracture in women with rheumatoid arthritis.
Spector, T. D., Hall, G. M., McCloskey, E. V., & Kanis, J. A. (1993) · BMJ · doi:10.1136/bmj.306.6877.558 · Cited by 230
COLWELL, A., RUSSELL, R. G. G., & EASTELL, R. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb02034.x · Cited by 181 · cited 1×
“Total deoxypyridinoline (adjusted for creatinine excretion) was measured by high-performance liquid chromatography [ 22 ].”
MethodSelf-citationFractures in rheumatoid arthritis: an evaluation of associated risk factors.
Michel, B. A., Bloch, D. A., Wolfe, F., & Fries, J. F. (1993) · PubMed · Cited by 146
Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study
Siris, E. S., Chines, A. A., Altman, R. D., Brown, J. P., Johnston, C. C., Lang, R., Mcclung, M. R., Mallette, L. E., Miller, P. D., Ryan, W. G., et al. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.6.1032 · Cited by 142 · cited 1×
“Risedronate hasbeenshownto normalizeboneturnoverandincrease bone massin patientswith multiple myeloma[17], to decrease serum calcium in patients with primary hyperparathyroi dism [18], and to suppress disease activity in patientswith Paget’sdiseaseof bone[19,20].”
BackgroundSelf-citationGough, A., Peel, N. F. A., Eastell, R., Holder, R. L., Lilley, J., & Emery, P. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.1.14 · Cited by 106 · cited 1×
“This could be related at least in part to the biological variability of bone resorption markers induced by systemic inflammation in patients with rheumatoid arthritis [ 26 ].”
BackgroundSelf-citationReasner, C. A., Stone, M. D., Hosking, D. J., Ballah, A., & Mundy, G. R. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.4.8408454 · Cited by 93
Roux, C., Ravaud, P., Cohen-Solal, M. E., de Vernejoul, M. C., Guillemant, S., Cherruau, B., Delmas, P. D., Dougados, M., & Amor, B. (1994) · Bone · doi:10.1016/8756-3282(94)90890-7 · Cited by 81 · cited 1×
“Risedronate has been shown to normalize bone turnover and increase bone mass in patients with multiple myeloma [ 17 ], to decrease serum calcium in patients with primary hyperparathyroidism [18], and to suppress disease activity in patients with Paget’s disease of bone [19,20].”
BackgroundPaget’s Disease of Bone: Reduction of Disease Activity With Oral Risedronate
Hosking, D. J., Eusebio, R. A., & Chines, A. A. (1998) · Bone · doi:10.1016/s8756-3282(97)00222-6 · Cited by 73
Self-citationEffects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica
Dolan, A. L., Moniz, C. F., Li, F., Mackintosh, C., Todd, P., Dasgupta, B., Corrigall, V., & Panayi, G. S. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401115 · Cited by 62 · cited 1×
“It hasbeenshownthat diseaseactivity is a significant determinantof bone loss in patientswith polymyalgiarheumatica[27].”
BackgroundRates of Bone Loss in Peri- and Postmenopausal Women: A 4 Year, Prospective, Population-Based Study
Young, R., May, H., Murphy, S. W., Grey, C., & Compston, J. E. (1996) · Clinical Science · doi:10.1042/cs0910307 · Cited by 26
Preclinical pharmacology of risedronate, a 3rd generation bisphosphonate
McOsker, J. E. (1990) · Bone and Mineral · doi:10.1016/0169-6009(90)90351-f · Cited by 7
Risedronate is effective and well tolerated in treating corticosteroid-induced osteoporosis.
Reid, D. B. W., Devogelaer, J., Hughes, R., Laan, R. F. J. M., Адами, С., Sacco-Gibson, N., & Wenderoth, D. (1998) · Arthritis & Rheumatism · Cited by 6
Self-citation
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
An overview and management of osteoporosis
Sözen, T., Özışık, L., & Çalık Başaran, N. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2016.048 · Cited by 2,262
“A drug holiday of up to 1 year after 7 years of therapy has been suggested (42).”
BackgroundThe clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
“Actonel® is approved to increase bone mass in men with osteoporosis and to prevent and treat osteoporosis in men and women who are either initiating or taking glucocorticoids [158, 159].”
BackgroundHodgson, S. F., Watts, N. B., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Harris, D. W., Conrad Johnston, C., Kleerekoper, M., Lindsay, R., Luckey, M. M., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.544 · Cited by 605
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
“For the bisphosphonates, alendronate [77–81], etidronate [82–91], risedronate [92–96] and zoledronic acid [97], and for the osteoanabolic, teriparatide, there is good evidence from placebo-controlled or comparator studies of beneficial effects on spine and hip BMD [98, 99].”
BackgroundSelf-citation
Metadata
- Authors
- Eastell, R., Devogelaer, J.-P., Peel, N. F. A., Chines, A. A., Bax, D. E., Sacco-Gibson, N., Nagant de Deuxchaisnes, C., & Russell, R. G. G.
- Affiliations
- University of Sheffield (GB)
- Procter & Gamble (United States) (US)
- Venue
- Osteoporosis International
- Published
- 2000-05-01
- Volume
- 11
- Issue
- 4
- Pages
- 331-337
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2018601087
- Cited by
- 134
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- risedronate, bone mineral density, bone loss prevention, rheumatoid arthritis, glucocorticoid-induced osteoporosis, postmenopausal women, bisphosphonates, prednisolone, lumbar spine, femoral neck, trochanter, treatment withdrawal
- MeSH terms
- Risedronic Acid, Administration, Oral, Aged, Arthritis, Rheumatoid, Calcium Channel Blockers, Double-Blind Method, Female, Glucocorticoids, Humans, Osteoporosis, Prednisolone, Etidronic Acid, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.